Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q13084

UPID:
RM28_HUMAN

ALTERNATIVE NAMES:
39S ribosomal protein L28, mitochondrial; Melanoma antigen p15; Melanoma-associated antigen recognized by T-lymphocytes

ALTERNATIVE UPACC:
Q13084; B2RCM4; D3DU46; Q4TT39; Q96S26; Q9BQD8; Q9BR04

BACKGROUND:
Large ribosomal subunit protein bL28m, identified by alternative names such as 39S ribosomal protein L28, mitochondrial, Melanoma antigen p15, and Melanoma-associated antigen recognized by T-lymphocytes, is integral to mitochondrial protein synthesis. This protein's function underscores the importance of the mitochondrial ribosome in cellular energy mechanisms and metabolic pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Large ribosomal subunit protein bL28m holds promise for unveiling new therapeutic avenues. Given its pivotal role in mitochondrial protein synthesis, targeting this protein could lead to innovative treatments for metabolic diseases and conditions stemming from mitochondrial impairments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.